-
A Breakthrough for Rare Disease: FDA Approves Joenja for APDS
NASDAQ: $PHAR A New Chapter for Families Affected by APDS In a significant milestone for medical science, the U.S. Food and Drug Administration (FDA) has officially approved Joenja (leniolisib). This approval marks a historic moment as the first-ever treatment specifically indicated for patients 12 years of age and older diagnosed with Activated Phosphoinositide 3-kinase delta…
-
Big News for APDS: FDA Grants Priority Review for Leniolisib in Younger Children
NASDAQ: $PHAR Pharming Group has just shared exciting developments regarding their treatment for Activated PI3K-delta Syndrome (APDS). The U.S. Food and Drug Administration (FDA) has formally accepted the supplemental New Drug Application (sNDA) for leniolisib and, significantly, granted it Priority Review status. This is a pivotal moment for the APDS community, particularly for families managing…